# Retatrutide

Canonical source: https://retacompare.com/encyclopedia/retatrutide

Triple agonist of GLP-1, GIP and glucagon receptors. Glucagon arm increases energy expenditure on top of incretin-driven satiety and insulinotropic effects.

Reference facts

Also known asLY3437943CategoryGLP-1 & MetabolicMechanism of actionTriple agonist of GLP-1, GIP and glucagon receptors. Glucagon arm increases energy expenditure on top of incretin-driven satiety and insulinotropic effects.TargetsGLP-1R, GIPR, GCGRIndications under research or approvedObesity, Type 2 Diabetes, MASHRegulatory status (reference entry)Investigational (Phase 3 — TRIUMPH program)Half-life~124 hours (~5–6 days)SequenceYXEGTFTSDYSIYLDKKAQEAFVNWLLAGGPSSGAPPPSSequence notesTriple agonist (GLP-1 / GIP / glucagon) with two C20 fatty diacid linkers and Aib substitutions at positions 2 and 13 (X = α-Aminoisobutyric acid). Representative backbone shown.Molecular weight (Da)4731Originator / sponsorEli LillyFirst reported2022OriginDisclosed at the 2022 ADA Scientific Sessions; first-in-human data published NEJM 2023.
    Primary References

Jastreboff et al., NEJM 2023 (Retatrutide Phase 2 obesity)

Rosenstock et al., Lancet 2023 (Retatrutide Phase 2 T2D)

TRIUMPH-1 (NCT05882045)


    Explore research articles about Retatrutide


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- Jastreboff et al., NEJM 2023 (Retatrutide Phase 2 obesity): https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
- Rosenstock et al., Lancet 2023 (Retatrutide Phase 2 T2D): https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01053-X/fulltext
- TRIUMPH-1 (NCT05882045): https://clinicaltrials.gov/study/NCT05882045